TY - JOUR
TI - Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from
the EPIC cohort, plus a meta-analysis of prospective studies
AU - Rinaldi, Sabina
AU - Cleveland, Rebecca
AU - Norat, Teresa
AU - Biessy,
AU - Carine
AU - Rohrmann, Sabine
AU - Linseisen, Jakob
AU - Boeing, Heiner and
AU - Pischon, Tobias
AU - Panico, Salvatore
AU - Agnoli, Claudia
AU - Palli,
AU - Domenico
AU - Tumino, Rosario
AU - Vineis, Paolo
AU - Peeters, Petra H. M.
AU - and van Gils, Carla H.
AU - Bueno-de-Mesquita, Bas H.
AU - Vrieling, Alina
AU - and Allen, Naomi E.
AU - Roddam, Andrew
AU - Bingham, Sheila
AU - Khaw,
AU - Kay-Tee
AU - Manjer, Jonas
AU - Borgquist, Signe
AU - Dumeaux, Vanessa and
AU - Gram, Inger Torhild
AU - Lund, Eiliv
AU - Trichopoulou, Antonia and
AU - Makrygiannis, Georgios
AU - Benetou, Vassiliki
AU - Molina, Esther and
AU - Donate Suarez, Ignacio
AU - Barricarte Gurrea, Aurelio
AU - Gonzalez,
AU - Carlos A.
AU - Tormo, Maria-Jose
AU - Altzibar, Jone M.
AU - Olsen, Anja
AU - and Tjonneland, Anne
AU - Gronbaek, Henning
AU - Overvad, Kim and
AU - Clavel-Chapelon, Francoise
AU - Boutron-Ruault, Marie-Christine and
AU - Morois, Sophie
AU - Slimani, Nadia
AU - Boffetta, Paolo
AU - Jenab, Mazda
AU - and Riboli, Elio
AU - Kaaks, Rudolf
JO - International Journal  of Cancer
PY - 2010
VL - 126
TODO - 7
SP - 1702-1715
PB - Wiley-Blackwell
SN - 0020-7136
TODO - 10.1002/ijc.24927
TODO - insulin-like growth factor-I (IGF-I); colorectal neoplasms; nested case
control study; European Prospective Investigation into Cancer (EPIC);
meta-analysis
TODO - Several prospective studies have shown a moderate positive association
between increasing circulating insulin-like growth factor-I (IGF-I)
levels and colorectal cancer risk. However, the associations were often
statistically nonsignificant, and the relationship of cancer risk with
IGF-I’s major binding protein, IGFBP-3, showed major discrepancies
between studies. We investigated the association of colorectal cancer
risk with serum IGF-I, total and intact IGFBP-3, in a case-control study
nested within the EPIC cohort (1,121 cases of colorectal cancer and
1,121 matched controls). Conditional logistic regression was used to
adjust for possible confounders. Our present study results were combined
in a meta-analysis with those from 9 previous prospective studies to
examine the overall evidence for a relationship of prediagnostic serum
IGF-I with colorectal cancer risk. In the EPIC study, serum
concentrations of IGF-I and IGFBP-3 showed no associations with risk of
colorectal cancer overall. Only in subgroup analyses did our study show
moderate positive associations of IGF-I levels with risk, either among
younger participants only (and only for colon cancer) or among
participants whose milk intakes were in the lowest tertile of the
population distribution (RR for an increase of 100 ng/ml = 1.43 [95%
CI = 1.13-1.93]). Nevertheless, in the meta-analysis a modest positive
association remained between serum IGF-I and colorectal cancer risk
overall (RR = 1.07 [1.01-1.14] for 1 standard deviation increase in
IGF-I). Overall, data from our present study and previous prospective
studies combined indicate a relatively modest association of colorectal
cancer risk with serum IGF-I.
ER -